Compare JRS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JRS | PLX |
|---|---|---|
| Founded | 2001 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.6M | 207.1M |
| IPO Year | N/A | 1996 |
| Metric | JRS | PLX |
|---|---|---|
| Price | $7.48 | $2.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 60.6K | ★ 940.5K |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $65.42 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.12 | $1.65 |
| 52 Week High | $8.90 | $3.19 |
| Indicator | JRS | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 55.28 |
| Support Level | $7.12 | $2.54 |
| Resistance Level | $8.32 | $3.19 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 22.52 | 60.14 |
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund s investment objective is to provide total return through high current income and capital appreciation.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.